We are developing a portfolio of potentially first-in-class and best-in-class compounds with the aim of improving patient outcomes and easing the burden that mental health conditions have on individuals, healthcare systems and society.
Our next-generation psychedelic-based treatments have been designed to be administered in a short clinic visit, be well-tolerated and deliver rapid, robust and lasting treatment effects.
Our synthetic, proprietary, intranasal formulation of 5-MeO-DMT benzoate. It is currently under investigation in Phase II studies as a potential medication for depression and alcohol use disorder.
Our synthetic, proprietary, intravenous formulation of psilocin benzoate. It is currently under investigation in Phase II studies as a potential medication for depression.
We also have several new chemical entities (NCEs) in preclinical development.
Our novel synthetic intranasal formulation of 5-MeO-DMT benzoate
Treatment with BPL-003 comprises administration of BPL-003 in a clinical setting, with pre-dose preparation, in-dose safety monitoring and post-dose follow-up provided by healthcare professionals to support patients and ensure the safe use of the compound.Â
The BPL-003 treatment has been designed to overcome some of the challenges of first-generation psychedelics and existing mental health treatments and produce rapid, robust and lasting treatment effects with a short time in clinic of 2 hours.Â
Rapid, robust and lasting response from a single dose
Findings from an open-label Phase IIa study investigating 10mg of BPL-003 in patients with Treatment Resistant Depression (depression that failed to respond to two or more prior treatments) who were not taking concomitant antidepressants found that:
A single administration of BPL-003 demonstrated a rapid antidepressant effect, with 55% of patients having a 50% or greater improvement in depression symptoms the day after dosing (day 2).
A robust and lasting antidepressant effect was shown, with 55% of patients meeting the criteria for remission from symptoms of depression at day 29 and 45% in remission at day 85.Â
BPL-003 required a short time in clinic, with patients deemed dischargeable within an average time of less than 2 hours. This underlies the potential to deliver a scalable treatment model that, if approved, could fit within the existing interventional psychiatry treatment paradigm.
Our novel synthetic intravenous formulation of psilocin benzoate
Treatment with ELE-101 comprises administration of ELE-101 in a clinical setting, with pre-dose preparation, in-dose safety monitoring and post-dose follow-up provided by healthcare professionals to support patients and ensure the safe use of the compound.Â
The ELE-101 treatment has been designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately 2 hours.
Links to other websites do not imply affiliation or endorsement. 51³Ô¹ÏÍø does not control and is not responsible for their content.
